심부전(HF) : 7대 시장 의약품 예측 및 시장 분석 - 업데이트판

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the heart failure market through 2032.

GlobalData estimates sales of HF therapeutics to be approximately $13.5 billion across the 7MM in 2022. By 2032, GlobalData expects the HF market to grow at a strong compound annual growth rate (CAGR) of 9.6%, reaching sales of $33.7 billion by the end of the forecast period.

Major drivers of HF market growth over the forecast period are the -

• Anticipated expanded indication for Bayer's Kerendia (finerenone)
• Launch of several oral and injectable agents
• Increase in the global prevalence of chronic HF

Major barriers that will restrict the growth of the HF market during the forecast period are the -

• High price of recently developed HF therapies
• General reluctance of cardiologists and other physicians to adopt and prescribe new HF therapies
• Widespread use of generic HF drugs, making it difficult for high-priced branded therapies to penetrate the market

Scope

• Overview of heart failure, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized heart failure therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the heart failure therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for heart failure treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global heart failure therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM heart failure therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM heart failure therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

• About GlobalData

1 Heart Failure: Executive Summary - Updated October 2024, Based on Events up to October 24, 2024

• 1.1 The HF market will exhibit strong growth between 2022 and 2032
• 1.2 Label expansions of CV drugs will fuel market growth
• 1.3 Unmet needs remain in the HF market despite the availability of well-established therapies
• 1.4 Injectable agents will dominate the HF market
• 1.5 What do physicians think?

2 Introduction - Updated October 2024, Based on Events up to October 24, 2024

• 2.1 Catalyst
• 2.2 Related reports

3 Disease Overview

• 3.1 Etiology and pathophysiology
  • 3.1.1 Etiology
  • 3.1.2 Pathophysiology
  • 3.1.3 Biomarkers/targets of interest
• 3.2 Classification or staging systems
• 3.3 Prognosis

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities
• 4.3 Global and historical trends
• 4.4 Forecast methodology
  • 4.4.1 Sources
  • 4.4.2 Forecast assumptions and methods
  • 4.4.3 Forecast assumptions and methods: diagnosed incident cases of HF - 7MM
  • 4.4.4 Forecast assumptions and methods: diagnosed incident cases of HF by ejection fraction
  • 4.4.5 Forecast assumptions and methods: hospitalizations for acute HF
  • 4.4.6 Forecast assumptions and methods: acute HF hospitalizations based on presentation
  • 4.4.7 Forecast assumptions and methods: hospital length of stay days for acute HF hospitalizations
  • 4.4.8 Forecast assumptions and methods: re-admissions within 30 days post-discharge after acute HF hospitalization
  • 4.4.9 Forecast assumptions and methods: diagnosed prevalent cases of HF - 7MM
  • 4.4.10 Forecast assumptions and methods: diagnosed prevalent cases of HF by ejection fraction
  • 4.4.11 Forecast assumptions and methods: diagnosed prevalent cases of HF by New York Heart Association classes
  • 4.4.12 Forecast assumptions and methods: diagnosed prevalent cases of HF with preserved ejection fraction (left ventricular ejection fraction >=50%) by New York Heart Association class
  • 4.4.13 Forecast assumptions and methods: diagnosed prevalent cases of HF with mid-range ejection fraction (left ventricular ejection fraction 40-49%) by New York Heart Association class
  • 4.4.14 Forecast assumptions and methods: diagnosed prevalent cases of HF with reduced ejection fraction (left ventricular ejection fraction <40%) by New York Heart Association class
  • 4.4.15 Forecast assumptions and methods: diagnosed prevalent cases of HF by American College of Cardiology Foundation/American Heart Association stages
• 4.5 Epidemiological forecast for HF (2022-32)
  • 4.5.1 Diagnosed incident cases of HF
  • 4.5.2 Age-specific diagnosed incident cases of HF
  • 4.5.3 Sex-specific diagnosed incident cases of HF
  • 4.5.4 Diagnosed incident cases of HF by ejection fraction
  • 4.5.5 Hospitalizations for acute HF
  • 4.5.6 Acute HF hospitalizations based on presentation
  • 4.5.7 Hospital length of stay for acute HF
  • 4.5.8 Re-admissions within 30 days post-discharge after acute HF
  • 4.5.9 Diagnosed prevalent cases of HF
  • 4.5.10 Age-specific diagnosed prevalent cases of HF
  • 4.5.11 Sex-specific diagnosed prevalent cases of HF
  • 4.5.12 Diagnosed prevalent cases of HF by ejection fraction
  • 4.5.13 Diagnosed prevalent cases of HF by New York Heart Association class
  • 4.5.14 Diagnosed prevalent cases of HF with preserved ejection fraction (left ventricle ejection fraction >=50%) by New York Heart Association class
  • 4.5.15 Diagnosed prevalent cases of HF with mid-range ejection fraction (left ventricle ejection fraction 40-49%) by New York Heart Association class
  • 4.5.16 Diagnosed prevalent cases of HF with reduced ejection fraction (left ventricle ejection fraction <40%) by New York Heart Association class
  • 4.5.17 Diagnosed prevalent cases of HF by American College of Cardiology Foundation/American Heart Association stages
• 4.6 Discussion
  • 4.6.1 Epidemiological forecast insight
  • 4.6.2 COVID-19 impact
  • 4.6.3 Limitations of the analysis
  • 4.6.4 Strengths of the analysis

5 Disease Management - Updated October 2024, Based on Events up to October 24, 2024

• 5.1 Diagnosis and treatment overview
• 5.2 KOL insights on disease management

6 Current Treatment Options - Updated October 2024, Based on Events up to October 24, 2024

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment - Updated October 2024, Based on Events up to October 24, 2024

• 7.1 Overview
• 7.2 Lack of therapies for HF with preserved ejection fraction patients
• 7.3 Lack of therapies for acute HF
• 7.4 Compliance and optimal management of HF treatments
• 7.5 Preventative therapies for patients at risk of developing HF

8 R&D Strategies - Updated October 2024, Based on Events up to October 24, 2024

• 8.1 Overview
  • 8.1.1 Label expansion for therapies approved for other indications
  • 8.1.2 Mergers and acquisitions to expand the product pipeline
• 8.2 Clinical trials design
  • 8.2.1 Clinical endpoints for HF
  • 8.2.2 Inclusion and exclusion criteria

9 Pipeline Assessment - Updated October 2024, Based on Events up to October 24, 2024

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis - Updated October 2024, Based on Events up to October 24, 2024

• 10.1 Overview
• 10.2 Competitive assessment

11 Current and Future Players - Updated October 2024, Based on Events up to October 24, 2024

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook - Updated October 2024, Based on Events up to October 24, 2024

• 12.1 Global markets
  • 12.1.1 Forecast
  • 12.1.2 Drivers and barriers - global issues
• 12.2 US
  • 12.2.1 Forecast
  • 12.2.2 Key events
  • 12.2.3 Drivers and barriers
• 12.3 5EU
  • 12.3.1 Forecast
  • 12.3.2 Key events
  • 12.3.3 Drivers and barriers
• 12.4 Japan
  • 12.4.1 Forecast
  • 12.4.2 Key events
  • 12.4.3 Drivers and barriers

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
  • 13.3.1 Forecasting methodology
• 13.4 Primary research - KOLs interviewed for this report
  • 13.4.1 KOLs
• 13.5 Primary research - prescriber survey
• 13.6 About the authors
  • 13.6.1 Analyst
  • 13.6.2 Therapy Area Director
  • 13.6.3 Epidemiologist
  • 13.6.4 Vice President of Disease Intelligence and Epidemiology
  • 13.6.5 Global Head of Pharma Research, Analysis, and Competitive Intelligence
• Contact Us